Breast Cancer

Testing Technology Improves Patient Selection for Herceptin Therapy

Published in Women's Health Weekly, September 7th, 2000

ChromaVision Medical Systems, Inc. (CVSN), San Juan Capistrano, California, announced completion of a fully blinded study demonstrating a dramatic improvement in pathologist accuracy and agreement among pathologists when Automated Cellular Imaging System (ACIS) was used to assist in qualifying a patient for Herceptin therapy.

Significantly, the study demonstrated that the pathologist who achieved the lowest accuracy manually (42%), when using ACIS, improved to an accuracy equal to that of the most accurate manual reader (91%).

The data from this study address concerns that current manual testing methods for determining whether a patient will...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2000-09-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry